Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Share-based Compensation (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Share-based Compensation data on record, last reported at $5.8 million in Q3 2025.

  • For Q3 2025, Share-based Compensation rose 50.89% year-over-year to $5.8 million; the TTM value through Sep 2025 reached $20.7 million, up 113.7%, while the annual FY2024 figure was $12.9 million, 344.62% up from the prior year.
  • Share-based Compensation reached $5.8 million in Q3 2025 per DNTH's latest filing, up from $5.7 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $5.8 million in Q3 2025 and bottomed at -$2.7 million in Q3 2022.
  • Average Share-based Compensation over 4 years is $2.3 million, with a median of $1.9 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: crashed 74.96% in 2023, then surged 571.21% in 2024.
  • A 4-year view of Share-based Compensation shows it stood at $513000.0 in 2022, then soared by 41.52% to $726000.0 in 2023, then surged by 439.67% to $3.9 million in 2024, then skyrocketed by 47.88% to $5.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $5.8 million in Q3 2025, $5.7 million in Q2 2025, and $5.3 million in Q1 2025.